Greenwich LifeSciences (NASDAQ:GLSI) Upgraded to Hold at Zacks Investment Research

Zacks Investment Research upgraded shares of Greenwich LifeSciences (NASDAQ:GLSI – Get Rating) from a sell rating to a hold rating in a report released on Friday, Zacks.com reports.

According to Zacks, “Greenwich LifeSciences Inc. is a clinical stage biopharmaceutical company focuses on the development of cancer immunotherapies for breast cancer and other human epidermal growth factor. The company’s product candidate includes GP2, which is in clinical stage. Greenwich LifeSciences Inc.is based in Stafford, Texas. “

Shares of NASDAQ:GLSI opened at $17.63 on Friday. Greenwich LifeSciences has a 12 month low of $15.52 and a 12 month high of $48.96. The stock’s fifty day moving average is $20.15.

In other Greenwich LifeSciences news, CEO Snehal Patel purchased 5,500 shares of the stock in a transaction on Friday, February 11th. The shares were purchased at an average cost of $19.80 per share, for a total transaction of $108,900.00. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders acquired a total of 13,300 shares of company stock worth $258,571 over the last quarter. Company insiders own 68.93% of the company’s stock.

Hedge funds have recently modified their holdings of the business. Renaissance Technologies LLC bought a new position in shares of Greenwich LifeSciences in the 4th quarter valued at about $730,000. BlackRock Inc. grew its position in shares of Greenwich LifeSciences by 9.2% in the 4th quarter. BlackRock Inc. now owns 237,959 shares of the company’s stock valued at $5,790,000 after acquiring an additional 20,105 shares during the period. Marshall Wace LLP bought a new position in shares of Greenwich LifeSciences in the 4th quarter valued at about $431,000. Millennium Management LLC grew its position in shares of Greenwich LifeSciences by 101.4% in the 4th quarter. Millennium Management LLC now owns 30,414 shares of the company’s stock valued at $740,000 after acquiring an additional 15,316 shares during the period. Finally, Tibra Equities Europe Ltd bought a new position in shares of Greenwich LifeSciences in the 3rd quarter valued at about $496,000. Hedge funds and other institutional investors own 6.25% of the company’s stock.

Greenwich LifeSciences Company Profile (Get Rating)

Greenwich LifeSciences, Inc, a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent recurrence of breast cancer following surgery.

Featured Stories